# Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid

> **NCT03746275** · — · COMPLETED · sponsor: **Bayer** · enrollment: 5798 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** Rivaroxaban (BAY59-7939, Xarelto)
- **DRUG:** Acetylsalicylic acid

## Key facts

- **NCT ID:** NCT03746275
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-13
- **Primary completion:** 2021-06-08
- **Final completion:** 2021-07-13
- **Target enrollment:** 5798 (ACTUAL)
- **Last updated:** 2022-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03746275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03746275, "Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT03746275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*